T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLB Ltd
SLB
|
+$2.48B |
| 2 |
Kenvue
KVUE
|
+$1.5B |
| 3 |
Halliburton
HAL
|
+$1.12B |
| 4 |
Boeing
BA
|
+$950M |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$920M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.64B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.66B |
| 4 |
Johnson & Johnson
JNJ
|
+$1.56B |
| 5 |
Amazon
AMZN
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.76% |
| 2 | Healthcare | 16.83% |
| 3 | Financials | 10.91% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Customers Bancorp
CUBI
$2.82B
| $407K | ﹤0.01% |
11,794
+265
| +2% | +$9.58K |
|
2202
Harmony Biosciences
HRMY
$2.24B
| $407K | ﹤0.01% |
12,398
+717
| +6% | +$24.9K |
|
2203
Viridian Therapeutics
VRDN
$2.49B
| $407K | ﹤0.01% |
26,525
+2,580
| +11% | +$49.2K |
|
2204
Recursion Pharmaceuticals
RXRX
$1.78B
| $406K | ﹤0.01% |
52,975
-23,851
| -31% | -$238K |
|
2205
MBIA
MBI
$262M
| $403K | ﹤0.01% |
55,850
+1,389
| +3% | +$11.6K |
|
2206
Arcturus Therapeutics
ARCT
$223M
| $402K | ﹤0.01% |
15,722
-3,535
| -18% | -$109K |
|
2207
Central Pacific Financial
CPF
$1B
| $402K | ﹤0.01% |
24,077
+7,853
| +48% | +$134K |
|
2208
Douglas Elliman
DOUG
$183M
| $400K | ﹤0.01% |
176,948
+13,954
| +9% | +$32.1K |
|
2209
Beazer Homes USA
BZH
$874M
| $398K | ﹤0.01% |
15,957
-4,816
| -23% | -$139K |
|
|
UMH
2210
UMH Properties
UMH
$1.42B
| $397K | ﹤0.01% |
28,270
+2,089
| +8% | +$32.1K |
|
|
CMRC
2211
Commerce.com Inc Series 1
CMRC
$184M
| $396K | ﹤0.01% |
40,104
+2,072
| +5% | +$21.6K |
|
2212
Orthofix Medical
OFIX
$415M
| $396K | ﹤0.01% |
30,744
-414
| -1% | -$7.45K |
|
|
NPKI
2213
NPK International
NPKI
$1.18B
| $396K | ﹤0.01% |
57,286
-16,900
| -23% | -$96.8K |
|
|
EHAB
2214
DELISTED
Enhabit
EHAB
| $394K | ﹤0.01% |
34,972
+1,245
| +4% | +$15.7K |
|
2215
Genesco
GCO
$394M
| $394K | ﹤0.01% |
12,755
+1,936
| +18% | +$54.9K |
|
2216
The RMR Group
RMR
$346M
| $393K | ﹤0.01% |
16,023
+1,656
| +12% | +$39.9K |
|
2217
PC Connection
CNXN
$2.04B
| $392K | ﹤0.01% |
7,343
+261
| +4% | +$13.3K |
|
|
MTTR
2218
DELISTED
Matterport, Inc. Class A Common Stock
MTTR
| $392K | ﹤0.01% |
180,634
+22,955
| +15% | +$64.3K |
|
2219
PagSeguro Digital
PAGS
$2.43B
| $391K | ﹤0.01% |
45,320
+5,098
| +13% | +$48K |
|
|
CHCT
2220
Community Healthcare Trust
CHCT
$433M
| $388K | ﹤0.01% |
13,057
+538
| +4% | +$18.1K |
|
|
HSII
2221
DELISTED
Heidrick & Struggles
HSII
| $388K | ﹤0.01% |
15,475
+3,761
| +32% | +$101K |
|
2222
Washington Trust Bancorp
WASH
$767M
| $388K | ﹤0.01% |
14,713
+6,023
| +69% | +$172K |
|
2223
MiMedx Group
MDXG
$612M
| $387K | ﹤0.01% |
53,029
-1,424
| -3% | -$10.6K |
|
|
VTLE
2224
DELISTED
Vital Energy
VTLE
| $387K | ﹤0.01% |
6,972
+1,065
| +18% | +$57.2K |
|
2225
American Vanguard Corp
AVD
$62.8M
| $386K | ﹤0.01% |
35,275
-22,859
| -39% | -$348K |
|
Similar funds
T. Rowe Price Associates's Q3 2023 Portfolio in Review
As of Q3 2023, T. Rowe Price Associates held 2,959 positions worth $682B, down 4.9% from $718B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 4.7%. T. Rowe Price Associates opened 69 new positions and exited 71, leaving the 2,959-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2023 buy was Maplebear: 6,435,942 shares worth $191M.
- T. Rowe Price Associates added most to SLB Ltd in Q3 2023, an estimated $2.48B increase.
- T. Rowe Price Associates's biggest Q3 2023 reduction was Microsoft, cutting an estimated $2.64B.
- T. Rowe Price Associates fully exited Life Storage, Inc. in Q3 2023, selling an estimated $285M.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $682B portfolio in Q3 2023.
- T. Rowe Price Associates opened 69 new positions and closed 71 in Q3 2023.
- T. Rowe Price Associates's portfolio value fell 4.9% quarter-over-quarter to $682B.
Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.